Top

European Journal of Medical Research

Published in:

Open Access 01-12-2014 | Research

The roles of mitoferrin-2 in the process of arsenic trioxide-induced cell damage in human gliomas

Authors: Chunlei Wang, Xiaofeng Chen, Huichao Zou, Xin Chen, Yaohua Liu, Shiguang Zhao

Published in: European Journal of Medical Research | Issue 1/2014

Abstract

Background

Among glioma treatment strategies, arsenic trioxide (As₂O₃) has shown efficacy as a therapeutic agent against human gliomas. However, the exact antitumor mechanism of action of As₂O₃ is still unclear. Mitochondria are considered to be the major source of intracellular reactive oxygen species (ROS), which are known to be associated with As₂O₃-induced cell damage. Therefore, we investigated whether mitoferrin-2, a mitochondrial iron uptake transporter, participates in As₂O₃-induced cell killing in human gliomas.

Methods

Human glioma cell lines were used to explore the mechanism of As₂O₃’s antitumor effects. First, expression of mitoferrin-2 was analyzed in glioma cells that were pretreated with As₂O_3. Changes in ROS production and apoptosis were assessed. Furthermore, cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT).

Results

In the present study we found that As₂O₃ induced ROS production and apoptosis in glioma cells. In addition, gene expression of mitoferrin-2, a mitochondrial iron uptake transporter, was increased 4 to 5 fold after exposure to As₂O₃ (5 μM) for 48 hours. Furthermore, apoptosis and cytotoxicity induced by As₂O₃ in glioma cells were decreased after silencing the mitoferrin-2 gene.

Conclusions

Our findings indicated that mitoferrin-2 participates in mitochondrial ROS-dependent mechanisms underlying As₂O₃-mediated damage in glioma cells.

Available only for authorised users

Song X, Chen Z, Wu C, Zhao S: Abrogating HSP response augments cell death induced by As2O3 in glioma cell lines. Can J Neurol Sci 2010, 37(4):504–511.PubMedCrossRef

Haga N, Fujita N, Tsuruo T: Involvement of mitochondrial aggregation in arsenic trioxide (As2O3)-induced apoptosis in human glioblastoma cells. Cancer Sci 2005, 96(11):825–833. 10.1111/j.1349-7006.2005.00114.xPubMedCrossRef

Yu M, Xue J, Li Y, Zhang W, Ma D, Liu L, Zhang Z: Resveratrol protects against arsenic trioxide-induced nephrotoxicity by facilitating arsenic metabolism and decreasing oxidative stress. Arch Toxicol 2013, 87(6):1025–1035. 10.1007/s00204-013-1026-4PubMedCrossRef

Murphy MP: How mitochondria produce reactive oxygen species. Biochem J 2009, 417: 1–13. 10.1042/BJ20081386PubMedPubMedCentralCrossRef

Swanson CA: Iron intake and regulation: implications for iron deficiency and iron overload. Alcohol 2003, 30(2):99–102. 10.1016/S0741-8329(03)00103-4PubMedCrossRef

Kohgo Y, Ohtake T, Ikuta K, Suzuki Y, Hosoki Y, Saito H, Kato J: Iron accumulation in alcoholic liver diseases. Alcohol Clin Exp Res 2005, 29(11):189S-193S. 10.1097/01.alc.0000189274.00479.62PubMedCrossRef

Petersen DR: Alcohol, iron-associated oxidative stress, and cancer. Alcohol 2005, 35(3):243–249. 10.1016/j.alcohol.2005.03.013PubMedCrossRef

Imeryuz N, Tahan V, Sonsuz A, Eren F, Uraz S, Yuksel M, Akpulat S, Ozcelik D, Haklar G, Celikel C, Avsar E, Tozun N: Iron preloading aggravates nutritional steatohepatitis in rats by increasing apoptotic cell death. J Hepatol 2007, 47(6):851–859. 10.1016/j.jhep.2007.06.018PubMedCrossRef

Britton RS, Leicester KL, Bacon BR: Iron toxicity and chelation therapy. Int J Hematol 2002, 76(3):219–228. 10.1007/BF02982791PubMedCrossRef

10.

Eaton JW, Qian M: Molecular bases of cellular iron toxicity. Free Radic Biol Med 2002, 32: 833–840. 10.1016/S0891-5849(02)00772-4PubMedCrossRef

11.

Shaw GC, Cope JJ, Li L, Corson K, Hersey C, Ackermann GE, Gwynn B, Lambert AJ, Wingert RA, Traver D, Trede NS, Barut BA, Zhou Y, Minet E, Donovan A, Brownlie A, Balzan R, Weiss MJ, Peters LL, Kaplan J, Zon LI, Paw BH: Mitoferrin is essential for erythroid iron assimilation. Nature 2006, 440: 96–100. 10.1038/nature04512PubMedCrossRef

12.

Uchiyama A, Kim JS, Kon K, Jaeschke H, Ikejima K, Watanabe S, Lemasters JJ: Translocation of iron from lysosomes into mitochondria is a key event during oxidative stress-induced hepatocellular injury. Hepatology 2008, 48: 1644–1654. 10.1002/hep.22498PubMedPubMedCentralCrossRef

13.

Vineetha VP, Prathapan A, Soumya RS, Raghu KG: Arsenic trioxide toxicity in H9c2 myoblasts - damage to cell organelles and possible amelioration with Boerhavia diffusa . Cardiovasc Toxicol 2013, 13(2):123–137. 10.1007/s12012-012-9191-xPubMedCrossRef

14.

Richter C, Gogvadze V, Laffranchi R, Schlapbach R, Schweizer M, Suter M, Walter P, Yaffee M: Oxidants in mitochondria: from physiology to diseases. Biochim Biophys Acta 1995, 1271: 67–74. 10.1016/0925-4439(95)00012-SPubMedCrossRef

15.

Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, Huang P: Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006, 10: 241–252. 10.1016/j.ccr.2006.08.009PubMedCrossRef

16.

Krzywanski DM, Moellering DR, Fetterman JL, Dunham-Snary KJ, Sammy MJ, Ballinger SW: The mitochondrial paradigm for cardiovascular disease susceptibility and cellular function: a complementary concept to Mendelian genetics. Lab Invest 2011, 91(8):1122–1135. 10.1038/labinvest.2011.95PubMedCrossRef

17.

Satre M, Mattei S, Aubry L, Gaudet P, Pelosi L, Brandolin G, Klein G: Mitochondrial carrier family: repertoire and peculiarities of the cellular slime mould Dictyostelium discoideum . Biochimie 2007, 89: 1058–1069. 10.1016/j.biochi.2007.03.004PubMedCrossRef

18.

Froschauer EM, Schweyen RJ, Wiesenberger G: The yeast mitochondrial carrier proteins Mrs3p/Mrs4p mediate iron transport across the inner mitochondrial membrane. Biochim Biophys Acta 2009, 1788: 1044–1050. 10.1016/j.bbamem.2009.03.004PubMedCrossRef

19.

Paradkar PN, Zumbrennen KB, Paw BH, Ward DM, Kaplan J: Regulation of mitochondrial iron import through differential turnover of mitoferrin 1 and mitoferrin 2. Mol Cell Biol 2009, 29: 1007–1016. 10.1128/MCB.01685-08PubMedPubMedCentralCrossRef

20.

Hung HI, Schwartz JM, Maldonado EN, Lemasters JJ, Nieminen AL: Mitoferrin-2-dependent mitochondrial iron uptake sensitizes human head and neck squamous carcinoma cells to photodynamic therapy. J Biol Chem 2013, 288(1):677–686. 10.1074/jbc.M112.422667PubMedPubMedCentralCrossRef

21.

Liu Y, Zhang X, Liang Y, Yu H, Chen X, Zheng T, Zheng B, Wang L, Zhao L, Shi C, Zhao S: Targeting X box-binding protein-1 (XBP1) enhances sensitivity of glioma cells to oxidative stress. Neuropathol Appl Neurobiol 2011, 37: 395–405. 10.1111/j.1365-2990.2010.01155.xPubMedCrossRef

22.

Yi J, Yang J, He R, Gao F, Sang H, Tang X, Ye RD: Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res 2004, 64: 108–116. 10.1158/0008-5472.CAN-2820-2PubMedCrossRef

23.

Kim JH, Lew YS, Kolozsvary A, Ryu S, Brown SL: Arsenic trioxide enhances radiation response of 9L glioma in the rat brain. Radiat Res 2003, 160(6):662–666. 10.1667/RR3069PubMedCrossRef

24.

Kanzawa T, Zhang L, Xiao L, Germano IM, Kondo Y, Kondo S: Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene 2005, 24(6):980–991. 10.1038/sj.onc.1208095PubMedCrossRef

25.

Cohen KJ, Gibbs IC, Fisher PG, Hayashi RJ, Macy ME, Gore L: A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood. Neuro Oncol 2013, 15(6):783–787. 10.1093/neuonc/not021PubMedPubMedCentralCrossRef

26.

Cai BZ, Meng FY, Zhu SL, Zhao J, Liu JQ, Liu CJ, Chen N, Ye ML, Li ZY, Ai J, Lu YJ, Yang BF: Arsenic trioxide induces the apoptosis in bone marrow mesenchymal stem cells by intracellular calcium signal and caspase-3 pathways. Toxicol Lett 2010, 193: 173–178. 10.1016/j.toxlet.2010.01.001PubMedCrossRef

27.

Yadav S, Shi Y, Wang F, Wang H: Arsenite induces apoptosis in human mesenchymal stem cells by altering Bcl-2 family proteins and by activating intrinsic pathway. Toxicol Appl Pharmacol 2010, 244: 263–272. 10.1016/j.taap.2010.01.001PubMedCrossRef

28.

Raghu KG, Cherian OL: Characterization of cytotoxicity induced by arsenic trioxide (a potent anti-APL drug) in rat cardiac myocytes. J Trace Elem Med Biol 2009, 23: 61–68. 10.1016/j.jtemb.2008.10.001PubMedCrossRef

29.

Li JX, Shen YQ, Cai BZ, Zhao J, Bai X, Lu YJ, Li XQ: Arsenic trioxide induces the apoptosis in vascular smooth muscle cells via increasing intracellular calcium and ROS formation. Mol Biol Rep 2010, 37: 1569–1576. 10.1007/s11033-009-9561-zPubMedCrossRef

30.

Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997, 89: 3354–3360.PubMed

31.

Yen YP, Tsai KS, Chen YW, Huang CF, Yang RS, Liu SH: Arsenic induces apoptosis in myoblasts through a reactive oxygen species-induced endoplasmic reticulum stress and mitochondrial dysfunction pathway. Arch Toxicol 2012, 86(6):923–933. 10.1007/s00204-012-0864-9PubMedCrossRef

32.

Kroemer G, de The H: Arsenic trioxide, a novel mitochondriotoxic anticancer agent? J Natl Cancer Inst 1999, 91: 743–745. 10.1093/jnci/91.9.743PubMedCrossRef

33.

Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, Tang W, Shi GY, Sun YP, Dai J, Wang ZY, Chen SJ, Zhang TD, Waxman S, Chen Z, Chen GQ: Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999, 91: 772–778. 10.1093/jnci/91.9.772PubMedCrossRef

34.

Mahieux R, Pise-Masison C, Gessain A, Brady JN, Olivier R, Perret E, Misteli T, Nicot C: Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 2001, 98: 3762–3769. 10.1182/blood.V98.13.3762PubMedCrossRef

35.

Kajiguchi T, Yamamoto K, Hossain K, Akhand AA, Nakashima I, Naoe T, Saito H, Emi N: Sustained activation of c-jun-terminal kinase (JNK) is closely related to arsenic trioxide-induced apoptosis in an acute myeloid leukemia (M2)-derived cell line, NKM-1. Leukemia 2003, 17: 2189–2195. 10.1038/sj.leu.2403120PubMedCrossRef

36.

Maeda H, Hori S, Nishitoh H, Ichijo H, Ogawa O, Kakehi Y, Kakizuka A: Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 2001, 61: 5432–5440.PubMed

37.

Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S: Mechanisms of action of arsenic trioxide. Cancer Res 2002, 62: 3893–3903.PubMed

38.

Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S: Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999, 94: 2102–2111.PubMed

39.

Boonstra J, Post JA: Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene 2004, 4(337):1–13. 10.1016/j.gene.2004.04.032CrossRef

40.

Kanda Y, Hinata T, Kang SW, Watanabe Y: Reactive oxygen species mediate adipocyte differentiation in mesenchymal stem cells. Life Sci 2011, 89(7-8):250–258. 10.1016/j.lfs.2011.06.007PubMedCrossRef

41.

Orrenius S: Reactive oxygen species in mitochondria-mediated cell death. Drug Metab Rev 2007, 39(2-3):443–455. 10.1080/03602530701468516PubMedCrossRef

42.

Antonsson B, Montessuit S, Sanchez B, Martinou JC: Bax is present as a high molecular weight oligomer/complex in the mitochondrial membrane of apoptotic cells. J Biol Chem 2001, 276(15):11615–11623. 10.1074/jbc.M010810200PubMedCrossRef

43.

Huang ML, Becker EM, Whitnall M, Suryo Rahmanto Y, Ponka P, Richardson DR: Elucidation of the mechanism of mitochondrial iron loading in Friedreich’s ataxia by analysis of a mouse mutant. Proc Natl Acad Sci U S A 2009, 106: 16381–16386. 10.1073/pnas.0906784106PubMedPubMedCentralCrossRef

44.

Yaguang R, Su Y, Tan G, Ye W, Liu D, Qian X, Ding Z, Zhong Y, Zhang J, Jiang D, Zhao Y, Lu J: Reduction of mitoferrin results in abnormal development and extended lifespan in Caenorhabditis elegans . PLoS One 2012, 7(1):e29666. 10.1371/journal.pone.0029666CrossRef

Title: The roles of mitoferrin-2 in the process of arsenic trioxide-induced cell damage in human gliomas
Authors: Chunlei Wang
Xiaofeng Chen
Huichao Zou
Xin Chen
Yaohua Liu
Shiguang Zhao
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: European Journal of Medical Research / Issue 1/2014
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-014-0049-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The roles of mitoferrin-2 in the process of arsenic trioxide-induced cell damage in human gliomas

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Treatment of mild and moderate type-2 diabetes: open prospective trial with Hintonia latiflora extract

Clinical efficacy of radical nephrectomy versus nephron-sparing surgery on localized renal cell carcinoma

Secondary damage in left-sided frontal white matter detected by diffusion tensor imaging is correlated with executive dysfunction in patients with acute infarction at the ipsilateral posterior corona radiata

Increased CD44s and decreased CD44v6 RNA expression are associated with better survival in myxofibrosarcoma patients: a pilot study

Pseudopheochromocytoma induced by anxiolytic withdrawal

European Journal of Medical Research reviewer acknowledgement 2013